Literature DB >> 31704157

Reduced in vivo visual cortex GABA in schizophrenia, a replication in a recent onset sample.

Jong H Yoon1, Richard J Maddock2, Edward DongBo Cui3, Michael J Minzenberg4, Tara A Niendam2, Tyler Lesh2, Marjorie Solomon2, J Daniel Ragland2, Cameron Carter2.   

Abstract

The GABA deficit hypothesis remains one of the most compelling explanations for the information processing impairments in schizophrenia. However, much of the supportive evidence has been derived from post-mortem studies, whereas in vivo studies have largely yielded inconsistent results. We undertook this single voxel proton magnetic resonance (MRS) GABA study to test in a sample of recent onset patients the replicability of our prior finding of reduced early visual cortex GABA in schizophrenia. We also examined the possibility that antipsychotics could represent a significant confound by studying a small subsample of antipsychotic naïve subjects. 23 adults with recent onset schizophrenia and a demographically matched sample of 31 healthy control subjects underwent MRS using a MEGA PRESS sequence on a 3T MR scanner to measure GABA concentration in early visual cortex. To control for in-scanner head movement confounding the results, we quantified the amount of head movement during GABA scans to identify and exclude from analysis scans with excessive movement. Patients demonstrated significantly reduced GABA levels compared to control subjects, p = 0.029. GABA levels did not differ significantly between patients who were antipsychotic naïve (n = 7) and patients treated with antipsychotics. This replication in a recent onset sample suggest that diminished GABA in the visual cortex is a reliable finding, present in early phase of illness and not confounded by illness chronicity. Published by Elsevier B.V.

Entities:  

Keywords:  GABA; Magnetic resonance spectroscopy; Visual cortex

Mesh:

Substances:

Year:  2019        PMID: 31704157      PMCID: PMC7035988          DOI: 10.1016/j.schres.2019.10.025

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  41 in total

1.  Study of a new schizophrenomimetic drug; sernyl.

Authors:  E D LUBY; B D COHEN; G ROSENBAUM; J S GOTTLIEB; R KELLEY
Journal:  AMA Arch Neurol Psychiatry       Date:  1959-03

2.  Clinical implications of Brief Psychiatric Rating Scale scores.

Authors:  Stefan Leucht; John M Kane; Werner Kissling; Johannes Hamann; Eva Etschel; Rolf Engel
Journal:  Br J Psychiatry       Date:  2005-10       Impact factor: 9.319

Review 3.  Pathophysiologically based treatment interventions in schizophrenia.

Authors:  David A Lewis; Guillermo Gonzalez-Burgos
Journal:  Nat Med       Date:  2006-09       Impact factor: 53.440

4.  Elevated gamma-aminobutyric acid levels in chronic schizophrenia.

Authors:  Dost Ongür; Andrew P Prescot; Julie McCarthy; Bruce M Cohen; Perry F Renshaw
Journal:  Biol Psychiatry       Date:  2010-07-02       Impact factor: 13.382

5.  GABA concentration in schizophrenia patients and the effects of antipsychotic medication: a proton magnetic resonance spectroscopy study.

Authors:  Shin'Ya Tayoshi; Masahito Nakataki; Satsuki Sumitani; Kyoko Taniguchi; Sumiko Shibuya-Tayoshi; Shusuke Numata; Jun-ichi Iga; Shu-ichi Ueno; Masafumi Harada; Tetsuro Ohmori
Journal:  Schizophr Res       Date:  2009-12-22       Impact factor: 4.939

6.  Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics.

Authors:  S Akbarian; J J Kim; S G Potkin; J O Hagman; A Tafazzoli; W E Bunney; E G Jones
Journal:  Arch Gen Psychiatry       Date:  1995-04

7.  Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia.

Authors:  Takanori Hashimoto; H Holly Bazmi; Karoly Mirnics; Qiang Wu; Allan R Sampson; David A Lewis
Journal:  Am J Psychiatry       Date:  2008-02-15       Impact factor: 18.112

8.  7T Proton Magnetic Resonance Spectroscopy of Gamma-Aminobutyric Acid, Glutamate, and Glutamine Reveals Altered Concentrations in Patients With Schizophrenia and Healthy Siblings.

Authors:  Katharine N Thakkar; Lara Rösler; Jannie P Wijnen; Vincent O Boer; Dennis W J Klomp; Wiepke Cahn; René S Kahn; Sebastiaan F W Neggers
Journal:  Biol Psychiatry       Date:  2016-04-19       Impact factor: 13.382

9.  GABA and glutamate in schizophrenia: a 7 T ¹H-MRS study.

Authors:  Anouk Marsman; René C W Mandl; Dennis W J Klomp; Marc M Bohlken; Vincent O Boer; Anna Andreychenko; Wiepke Cahn; René S Kahn; Peter R Luijten; Hilleke E Hulshoff Pol
Journal:  Neuroimage Clin       Date:  2014-10-15       Impact factor: 4.881

10.  Visual perception and its impairment in schizophrenia.

Authors:  Pamela D Butler; Steven M Silverstein; Steven C Dakin
Journal:  Biol Psychiatry       Date:  2008-07-01       Impact factor: 13.382

View more
  3 in total

Review 1.  Galantamine-Memantine Combination and Kynurenine Pathway Enzyme Inhibitors in the Treatment of Neuropsychiatric Disorders.

Authors:  Michael Y Bai; David B Lovejoy; Gilles J Guillemin; Rouba Kozak; Trevor W Stone; Maju Mathew Koola
Journal:  Complex Psychiatry       Date:  2021-02-08

Review 2.  Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of 1H-magnetic resonance spectroscopy studies.

Authors:  Tomomi Nakahara; Sakiko Tsugawa; Yoshihiro Noda; Fumihiko Ueno; Shiori Honda; Megumi Kinjo; Hikari Segawa; Nobuaki Hondo; Yukino Mori; Honoka Watanabe; Kazuho Nakahara; Kazunari Yoshida; Masataka Wada; Ryosuke Tarumi; Yusuke Iwata; Eric Plitman; Sho Moriguchi; Camilo de la Fuente-Sandoval; Hiroyuki Uchida; Masaru Mimura; Ariel Graff-Guerrero; Shinichiro Nakajima
Journal:  Mol Psychiatry       Date:  2021-09-28       Impact factor: 15.992

3.  Stable habituation deficits in the early stage of psychosis: a 2-year follow-up study.

Authors:  Suzanne N Avery; Maureen McHugo; Kristan Armstrong; Jennifer Urbano Blackford; Neil D Woodward; Stephan Heckers
Journal:  Transl Psychiatry       Date:  2021-01-05       Impact factor: 6.222

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.